Compare HLX & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | AVLN |
|---|---|---|
| Founded | 1979 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1996 | 2026 |
| Metric | HLX | AVLN |
|---|---|---|
| Price | $8.71 | $30.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 321.4K |
| Earning Date | 04-22-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $876,561,000.00 | N/A |
| Revenue This Year | $2.05 | N/A |
| Revenue Next Year | $5.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $5.52 | $28.26 |
| 52 Week High | $10.75 | $33.24 |
| Indicator | HLX | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 37.13 | N/A |
| Support Level | $8.58 | N/A |
| Resistance Level | $10.54 | N/A |
| Average True Range (ATR) | 0.30 | 0.00 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 16.10 | 0.00 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.